CVS Health Corporation $CVS Holdings Cut by Jackson Square Capital LLC

Key Points

• Jackson Square Capital reduced its CVS Health stake by 26.4% in the third quarter, selling 11,475 shares and retaining 32,070 shares valued at approximately $2.75 million.
• CVS reported quarterly EPS of $2.58, exceeding the $1.87 consensus estimate, while revenue rose 7.3% year over year to $106.1 billion. The company maintained fiscal 2026 EPS guidance of $7.90–$8.10.
• Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $107.80 versus the stock’s reported price of $91.14. CVS also declared a quarterly dividend of $0.665, representing a 2.9% annualized yield.

Jackson Square Capital LLC cut its stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 26.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 32,070 shares of the pharmacy operator's stock after selling 11,475 shares during the period. Jackson Square Capital LLC's holdings in CVS Health were worth $2,748,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in CVS. BlackRock Inc. purchased a new stake in shares of CVS Health during the second quarter worth approximately $12,747,462,000. State Street Corp grew its position in CVS Health by 26.3% in the 2nd quarter. State Street Corp now owns 74,927,064 shares of the pharmacy operator's stock valued at $7,751,205,000 after buying an additional 15,604,883 shares during the last quarter. Wellington Management Group LLP increased its stake in CVS Health by 49.8% in the 2nd quarter. Wellington Management Group LLP now owns 33,801,113 shares of the pharmacy operator's stock valued at $3,496,725,000 after buying an additional 11,233,381 shares during the period. Bank of America Corp DE increased its stake in CVS Health by 148.0% in the 2nd quarter. Bank of America Corp DE now owns 23,188,670 shares of the pharmacy operator's stock valued at $2,398,868,000 after buying an additional 13,836,701 shares during the period. Finally, Pzena Investment Management LLC purchased a new position in CVS Health during the 2nd quarter worth $1,217,558,000. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Price Performance

CVS stock traded down $1.22 on Monday, reaching $91.14. 1,875,086 shares of the company's stock were exchanged, compared to its average volume of 8,343,972. The stock has a fifty day moving average of $91.74 and a 200-day moving average of $93.19. CVS Health Corporation has a twelve month low of $69.51 and a twelve month high of $110.68. The firm has a market cap of $116.57 billion, a PE ratio of 24.12, a P/E/G ratio of 0.86 and a beta of 0.60. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%. The firm had revenue of $106.10 billion during the quarter, compared to analysts' expectations of $100.03 billion. During the same quarter in the prior year, the business posted $1.81 earnings per share. CVS Health's revenue was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, equities analysts predict that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Thursday, October 22nd will be paid a $0.6650 dividend. The ex-dividend date is Thursday, October 22nd. This represents a $2.66 annualized dividend and a dividend yield of 2.9%. CVS Health's dividend payout ratio (DPR) is 70.37%.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on CVS. Wells Fargo & Company raised their target price on shares of CVS Health from $103.00 to $123.00 and gave the stock an "overweight" rating in a research note on Monday, July 13th. JPMorgan Chase & Co. boosted their price target on shares of CVS Health from $111.00 to $118.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 12th. Sanford C. Bernstein reiterated an "outperform" rating and set a $112.00 price target on shares of CVS Health in a research note on Wednesday, September 9th. Leerink Partners cut their price target on shares of CVS Health from $119.00 to $112.00 and set an "outperform" rating for the company in a report on Monday, October 12th. Finally, Bank of America raised their price objective on shares of CVS Health from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Monday, June 22nd. Twenty research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, CVS Health currently has a consensus rating of "Moderate Buy" and an average price target of $107.80.

CVS Health Company Profile

CVS Health Corporation NYSE: CVS is a diversified health care company that provides pharmacy, insurance and health services in the United States. Its businesses serve consumers, employers, health plans and health care providers through pharmacies, benefit programs, insurance coverage and clinical care services.

The company's Pharmacy Services segment, led by CVS Caremark, manages prescription drug benefits for employers, insurers and government programs. CVS Pharmacy operates retail pharmacies and health-focused stores that dispense prescriptions and offer over-the-counter products, health and wellness merchandise, immunizations and related services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.